The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of enterade in neuroendocrine tumor (NET) patients with quality-of-life limiting bowel movement frequency.
 
Satya Das
Honoraria - Lexicon; Lexicon; Lexicon; Lexicon; Medsphere; Medsphere; Medsphere; Medsphere; Targeted Oncology; Targeted Oncology; Targeted Oncology; Targeted Oncology
 
Tatsuki Koyama
No Relationships to Disclose
 
Laura Luque
Employment - Entrinsic Health Solutions; Entrinsic Health Solutions; Entrinsic Health Solutions; Entrinsic Health Solutions
 
Samuel Cheuvront
Employment - Entrinsic Health; Entrinsic Health; Entrinsic Health; Entrinsic Health
 
Jordan Berlin
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Arno Therapeutics; Arno Therapeutics; Arno Therapeutics; Arno Therapeutics; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Health; Bayer Health; Bayer Health; Bayer Health; Celgene; Celgene; Celgene; Celgene; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; ipsen; ipsen; ipsen; ipsen; lsk biopharma; lsk biopharma; lsk biopharma; lsk biopharma; qed therapeutics; qed therapeutics; qed therapeutics; qed therapeutics; Seagen; Seagen; Seagen; Seagen
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); boston biomedical (Inst); boston biomedical (Inst); boston biomedical (Inst); boston biomedical (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); pfizer (Inst); pfizer (Inst); pfizer (Inst); pfizer (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie; Bayer; Bayer; Bayer; Bayer; boston Biomedical; boston Biomedical; boston Biomedical; boston Biomedical; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Seagen; Seagen; Seagen; Seagen
Other Relationship - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca